Stock Scorecard
Stock Summary for Capricor Therapeutics Inc (CAPR) - $26.13 as of 1/7/2026 10:16:16 AM EST
Total Score
7 out of 30
Safety Score
30 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CAPR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CAPR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CAPR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CAPR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CAPR (30 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CAPR
Financial Details for CAPR
Company Overview |
|
|---|---|
| Ticker | CAPR |
| Company Name | Capricor Therapeutics Inc |
| Country | N/A |
| Description | Capricor Therapeutics, Inc. is an innovative biotechnology firm based in Beverly Hills, California, focused on developing advanced cell- and exosome-based therapies for a variety of diseases. The company is committed to regenerative medicine, utilizing its proprietary technologies to create solutions that address critical unmet medical needs. With a promising research and development pipeline and strong emphasis on scientific excellence, Capricor is strategically positioned to improve patient outcomes and forge key partnerships within the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 26.13 |
| Price 4 Years Ago | 3.86 |
| Last Day Price Updated | 1/7/2026 10:16:16 AM EST |
| Last Day Volume | 1,189,552 |
| Average Daily Volume | 4,314,415 |
| 52-Week High | 40.37 |
| 52-Week Low | 4.30 |
| Last Price to 52 Week Low | 507.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 25.63 |
| Sector PE | 58.77 |
| 5-Year Average PE | -5.63 |
| Free Cash Flow Ratio | 72.58 |
| Industry Free Cash Flow Ratio | 12.64 |
| Sector Free Cash Flow Ratio | 26.72 |
| Current Ratio Most Recent Quarter | 3.59 |
| Total Cash Per Share | 0.36 |
| Book Value Per Share Most Recent Quarter | 1.83 |
| Price to Book Ratio | 18.72 |
| Industry Price to Book Ratio | 4.16 |
| Sector Price to Book Ratio | 4.77 |
| Price to Sales Ratio Twelve Trailing Months | 141.05 |
| Industry Price to Sales Ratio Twelve Trailing Months | 46.20 |
| Sector Price to Sales Ratio Twelve Trailing Months | 22.08 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 54,399,000 |
| Market Capitalization | 1,421,445,870 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -81.57% |
| Reported EPS 12 Trailing Months | -1.75 |
| Reported EPS Past Year | -1.64 |
| Reported EPS Prior Year | -1.20 |
| Net Income Twelve Trailing Months | -81,989,635 |
| Net Income Past Year | -40,467,186 |
| Net Income Prior Year | -22,287,542 |
| Quarterly Revenue Growth YOY | -7.90% |
| 5-Year Revenue Growth | 85.83% |
| Operating Margin Twelve Trailing Months | -779.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 19,510,383 |
| Total Cash Past Year | 11,286,996 |
| Total Cash Prior Year | 14,694,857 |
| Net Cash Position Most Recent Quarter | 16,134,124 |
| Net Cash Position Past Year | 7,910,737 |
| Long Term Debt Past Year | 3,376,259 |
| Long Term Debt Prior Year | 3,376,259 |
| Total Debt Most Recent Quarter | 3,376,259 |
| Equity to Debt Ratio Past Year | 0.98 |
| Equity to Debt Ratio Most Recent Quarter | 0.96 |
| Total Stockholder Equity Past Year | 145,462,336 |
| Total Stockholder Equity Prior Year | 22,601,467 |
| Total Stockholder Equity Most Recent Quarter | 83,867,255 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -68,375,008 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.26 |
| Free Cash Flow Past Year | -41,534,717 |
| Free Cash Flow Prior Year | -27,644,078 |
Options |
|
| Put/Call Ratio | 1.52 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.61 |
| RSI | 66.58 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/5/2026 7:30:52 PM EST |